Effects of berberine on amelioration of hyperglycemia and oxidative stress in high glucose and high fat diet-induced diabetic hamsters in vivo

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Liu, Cong ^a   Wang, Zhuo ^b   Song, Yulong ^c   Wu, Dan ^a   Zheng, Xuan ^a   Li, Ping ^a   Jin, Jin ^b   Xu, Nannan ^b   Li, Ling ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b CAPITAL NORMAL UNIVERSITY   (China)

^c SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTANE; BERBERINE; FATTY ACID; GLUCOSE; GLUCOSE TRANSPORTER 4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; METFORMIN; SIMVASTATIN; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; LIPID; MESSENGER RNA; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; HYPERLIPIDEMIA; IN VIVO STUDY; INSULIN RELEASE; INSULIN SENSITIVITY; LIPID DIET; LIPID METABOLISM; LIPID STORAGE; NONHUMAN; OXIDATIVE STRESS; SKELETAL MUSCLE; SYRIAN HAMSTER; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BIOSYNTHESIS; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; GENE EXPRESSION; HAMSTER; MALE; MESOCRICETUS; MOUSE; PATHOLOGY;

CRICETINAE; MESOCRICETUS AURATUS; MUS;

ANIMALS; BERBERINE; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CRICETINAE; DIABETES MELLITUS, EXPERIMENTAL; DIET, HIGH-FAT; GENE EXPRESSION; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; INSULIN; LIPIDS; MALE; MESOCRICETUS; MICE; OXIDATIVE STRESS; RNA, MESSENGER; STREPTOZOCIN;

EID: 84924074554     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/313808     Document Type: Article

References (33)

1. M. Isfort, S. C. W. Stevens, S. Schaffer, C. J. Jong, and L. E. Wold, "Metabolic dysfunction in diabetic cardiomyopathy," Heart Failure Reviews, vol. 19, no. 1, pp. 35-48, 2014.
2. D. Gerö, P. Szoleczky, K. Suzuki et al., "Cell-based screening identifies paroxetine as an inhibitor of diabetic endothelial dysfunction," Diabetes, vol. 62, no. 3, pp. 953-964, 2013.
3. L. Cai and Y. J. Kang, "Oxidative stress and diabetic cardiomyopathy: a brief review," Cardiovascular Toxicology, vol. 1, no. 3, pp. 181-193, 2001.
4. T. Nishikawa, D. Edelstein, X. L. Du et al., "Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage," Nature, vol. 404, no. 6779, pp. 787-790, 2000.
5. H. Unoki and S.-I. Yamagishi, "Advanced glycation end products and insulin resistance," Current PharmaceuticalDesign, vol. 14, no. 10, pp. 987-989, 2008.
6. M. G. Rosca, T. G. Mustata, M. T. Kinter et al., "Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation," The American Journal of Physiology-Renal Physiology, vol. 289, no. 2, pp. F420-F430, 2005.
7. J. W. Baynes and S. R. Thorpe, "Role of oxidative stress in diabetic complications: a new perspective on an old paradigm," Diabetes, vol. 48, no. 1, pp. 1-9, 1999.
8. D. H. van Raalte and M. Diamant, "Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy?" Diabetes Research and Clinical Practice, vol. 93, supplement 1, pp. S37-S46, 2011.
9. N. Papanas and E. Maltezos, "Oral antidiabetic agents: antiatherosclerotic properties beyond glucose lowering?" Current Pharmaceutical Design, vol. 15, no. 27, pp. 3179-3192, 2009.
10. S. Coccheri, "Approaches to prevention of cardiovascular complications and events in diabetes mellitus," Drugs, vol. 67, no. 7, pp. 997-1026, 2007.
11. L. Jin, H.-Y. Xue, L.-J. Jin, S.-Y. Li, and Y.-P. Xu, "Antioxidant and pancreas-protective effect of aucubin on rats with streptozotocin-induced diabetes," European Journal of Pharmacology, vol. 582, no. 1-3, pp. 162-167, 2008.
12. G. Derosa, P. Maffioli, and A. F. G. Cicero, "Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials," ExpertOpinion on Biological Therapy, vol. 12, no. 8, pp. 1113-1124, 2012.
13. J. Zhou, S. Zhou, J. Tang et al., "Protective effect of berberine on beta cells in streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats," European Journal of Pharmacology, vol. 606, no. 1-3, pp. 262-268, 2009.
14. A. F. Cicero and E. Tartagni, "Antidiabetic properties of berberine: from cellular pharmacology to clinical effects," Hospital Practice, vol. 40, no. 2, pp. 56-63, 2012.
15. S. venkatesh, G. D. Reddy, Y. S. R. Reddy, D. Sathyavathy, and B. M. Reddy, "Effect of Helicteres isora root extracts on glucose tolerance in glucose-induced hyperglycemic rats," Fitoterapia, vol. 75, no. 3-4, pp. 364-367, 2004.
16. P. Yi, F.-E. Lu, L.-J. Xu, G. Chen, H. Dong, and K.-F. Wang, "Berberine reverses free-fatty-acid-induced insulin resistance in 3T3-L1 adipocytes through targeting IKKβ," World Journal of Gastroenterology, vol. 14, no. 6, pp. 876-883, 2008.
17. B.-S. Ko, S. B. Choi, S. K. Park, J. S. Jang, and Y. E. Kim, "Insulin sensitizing and insulinotropic action of berberine fromCortidis Rhizoma," Biological and Pharmaceutical Bulletin, vol. 28, no. 8, pp. 1431-1437, 2005.
18. W. Zhang, Y.-C. Xu, F.-J. Guo, Y. Meng, and M.-L. Li, "Antidiabetic effects of cinnamaldehyde and berberine and their impacts on retinol-binding protein 4 expression in rats with type 2 diabetes mellitus," Chinese Medical Journal, vol. 121, no. 21, pp. 2124-2128, 2008.
19. J. Yin, R. Hu, M. Chen et al., "Effects of berberine on glucose metabolism in vitro," Metabolism: Clinical and Experimental, vol. 51, no. 11, pp. 1439-1443, 2002.
20. Y. Zhang, X. Li, D. Zou et al., "Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine," The Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 7, pp. 2559-2565, 2008.
21. Y. S. Lee,W. S. Kim, K. H. Kimet al., "Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states," Diabetes, vol. 55, no. 8, pp. 2256-2264, 2006.
22. C. Huang, Y. Zhang, Z. Gong et al., "Berberine inhibits 3T3- L1 adipocyte differentiation through the PPARγ pathway," Biochemical and Biophysical Research Communications, vol. 348, no. 2, pp. 571-578, 2006.
23. T. Inaba, H. Yagyu, N. Itabashi et al., "Cholesterol reduction and atherosclerosis inhibition by bezafibrate in low-density lipoprotein receptor knockout mice," Hypertension Research, vol. 31, no. 5, pp. 999-1005, 2008.
24. A. Hammarstedt, C. X. Andersson, V. Rotter Sopasakis, and U. Smith, "The effect of PPARγ ligands on the adipose tissue in insulin resistance," Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 73, no. 1, pp. 65-75, 2005.
25. A.N. Lucchesi, N. T. de Freitas, L. L. Cassettari, S.F.G. Marques, and C. T. Spadella, "Diabetes mellitus triggers oxidative stress in the liver of alloxan-treated rats: a mechanism for diabetic chronic liver disease," Acta Cirurgica Brasileira, vol. 28, no. 7, pp. 502-508, 2013.
26. R.-L. Yang, Y.-H. Shi, G. Hao, W. Li, and G.-W. Le, "Increasing oxidative stress with progressive hyperlipidemia in human: relation between malondialdehyde and atherogenic index," Journal of Clinical Biochemistry and Nutrition, vol. 43, no. 3, pp. 154-158, 2008.
27. D. A. Slatter, C. H. Bolton, and A. J. Bailey, "The importance of lipid-derivedmalondialdehyde in diabetes mellitus," Diabetologia, vol. 43, no. 5, pp. 550-557, 2000.
28. S. Passi, M. Picardo, C. Zompetta, C. De Luca, A. S. Breathnach, and M. Nazzaro-Porro, "The oxyradical-scavenging activity of azelaic acid in biological systems," Free Radical Research Communications, vol. 15, no. 1, pp. 17-28, 1991.
29. A. Pandolfi and N. Di Pietro, "High glucose, nitric oxide, and adenosine: a vicious circle in chronic hyperglycaemia?" Cardiovascular Research, vol. 86, no. 1, pp. 9-11, 2010.
30. "The effect of intensive treatment of diabetes on the development and progresion of long-term complications in insulindependent diabetes millitus," The New England Journal of Medicine, vol. 329, no. 14, pp. 977-986, 1993.
31. D. M. Nathan and DCCT/EDIC Research Group, "The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview," Diabetes Care, vol. 37, no. 1, pp. 9-16, 2014.
32. R. C. Turner, H. Millns, H. A. W. Neil et al., "Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)," British Medical Journal, vol. 316, no. 7134, pp. 823-828, 1998.
33. P. King, I. Peacock, and R. Donnelly, "The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes," British Journal ofClinical Pharmacology, vol. 48, no. 5, pp. 643-648, 1999.